|
2019, Volume 35, Number 2, Page(s) 144-150
|
|
DOI: 10.5146/tjpath.2017.01385 |
Xanthogranulomatous Pancreatitis -A Rare Case Defying Clinical, Radiological and Tumor Marker Diagnostics with a Review of Literature |
Kavita GAUR1, Shramana MANDAL1, Nidhi MAHAJAN2, Sandeep SALUJA3, Satyajit GODHI3 |
1Department of Pathology, GB Pant Institute of Postgraduate Medical Education and Research, Jawaharlal Nehru Marg, NEW DELHI, INDIA, 2Maulana Azad Medical College, Bahadurshah Zafar Marg, NEW DELHI, INDIA 3Department of Gastrointestinal Surgery, GB Pant Institute of Postgraduate Medical Education and Research, Jawaharlal Nehru Marg, NEW DELHI, INDIA |
Keywords:
Pancreatitis, Xanthogranulomatous inflammation, CA 19-9 |
Xanthogranulomatous inflammation of the pancreas is an extremely rare entity mimicking pancreatic neoplasia. Elevation of tumor markers has
seldom been reported in xanthogranulomatous inflammation of the pancreas, rendering the diagnosis difficult and highlighting the importance
of a meticulous histopathological examination. A 58-year-old male presented with severe abdominal pain and anorexia for six months. A
heterogeneously enhancing solid cystic mass was detected in the pancreatic head on contrast enhanced computed tomography. Endoscopic
ultrasound guided aspiration yielded fluid showing elevated levels of CA19-9 (12000 IU/ml) and CEA (221ng/ml) with a concordant increase in
the serum tumour marker levels (CA 19-9:407 IU/ml; CEA: 70 ng /ml). Clinical, radiological and biochemical evidence favouring malignancy
prompted a Whipple's procedure. A thorough histopathological examination of the specimen failed to reveal malignancy. Sheets of macrophages
(CD 68 +, HAM 56 +), chronic inflammatory cells, fibroblasts and proliferating capillaries replacing most of the pancreatic parenchyma were
seen instead, nailing the diagnosis of xanthogranulomatous inflammation of the pancreas. To the best of our knowledge this is the first report of
xanthogranulomatous inflammation of the pancreas without associated malignancy displaying an elevation of serum and fluid tumour markers.
After seven months of follow up, the patient is asymptomatic and is doing well.
|
|
|
|